Jan. 17-21, 2023 • In Person and Virtual
2023 Program Schedule | Meeting Code of Conduct
OVERVIEW
Through this hybrid program attendees will have access to the best in cancer immunotherapy education taught by leading experts in the field. This program will provide a deep understanding of the core principles of tumor immunology and cancer immunotherapy as well as develop areas in the field including biomarker technology, validation and clinical integration; clinical trial design, data analysis and considerations for combination therapies. View the full program schedule here.
The program is tailored to early-to-mid career scientists and clinicians in the field of cancer immunotherapy working in academic, clinical, industry and government settings as well as those new to the field. The curriculum will cover the fundamentals of cancer immunotherapy and features separate tracks, including clinical and research, allowing participants to tailor their experience by selecting the educational path most relevant to their learning goals.
ORGANIZERS
- Christian Capitini, MD – University of Wisconsin-Madison
- Justin Eyquem, PhD – University of California San Francisco
- Daniel Powell, PhD – University of Pennsylvania
- Program Advisor: Catherine Bollard, MBChB, MD – Children’s National Hospital
Faculty
- Panagiotis Benos, PhD - University of Florida
- Lisa H. Butterfield, PhD - University of California San Francisco
- Deborah Collyar, BS - Patient Advocates in Research
- Tricia Cottrell, MD, PhD - Queen's University
- Greg Delgoffe, PhD - University of Pittsburgh
- Devaveena Dey, PhD - U.S. Food and Drug Administration
- Victor Engelhard, PhD - University of Virginia School of Medicine
- Maryland Franklin, PhD - Labcorp
- Elizabeth Garrett-Mayer, PhD - American Society of Clinical Oncology
- Sacha Gnjatic, PhD - Icahn School of Medicine at Mount Sinai
- Emmanuel Adu-Gyamfi, PhD - U.S. Food and Drug Administration
- Howard Kaufman, MD, FACS - Ankyra Therapeutics and Massachusetts General Hospital
- Dinesh Kumar, PhD - Parker Institute for Cancer Immunotherapy
- Lewis Lanier, PhD - University of California San Francisco
|
- Michael Lotze, MD, FACS - Nurix Therapeutics
- Jan Joseph Melenhorst, PhD - Cleveland Clinic
- Taha Merghoub, PhD - Weill Cornell Medicine
- Yana Najjar, MD - University of Pittsburgh
- Bradley Nelson, PhD - BC Cancer Deeley Research
- Robert Scharpf, PhD - Johns Hopkins University
- Nirali Shah, MD, MHSc - National Institute of Health
- Sumit Subudhi, MD, PhD -The University of Texas MD Anderson Cancer Center
- Ryan Sullivan, MD - Harvard Medical School and Massachusetts General Hospital
- Christopher Takimoto, MD, PhD - IGM Biosciences
- Irina Tiper, PhD - U.S. Food and Drug Administration
- Todd Triplett, PhD - Dell Medical School at the University of Texas
- Jennifer Wargo, MD, MMSc - The University of Texas MD Anderson Cancer Center
- Jianda Yuan, MD, PhD - Merck Research Laboratories
- Andrew Weinberg, PhD - Earle A. Chiles Research
|
TARGET AUDIENCE
- Early-to-mid career scientists in the field of cancer immunotherapy working in academic, clinical, industry and government settings
- Individuals new to the field working in academic, clinical, industry and government settings
NETWORKING OPPORTUNITIES
In addition to deepening their understanding of integral facets of the field of cancer immunotherapy, attendees will have opportunities to expand their professional network, developing new relationships with faculty and other thought leaders through small group breakout sessions and virtual networking features.
LEARNING OBJECTIVES
Upon completion of the Cancer Immunotherapy Winter School, participants are able to:
- Describe the core principles of tumor immunology and cancer immunotherapy
- Discuss recent advancements in drug and biomarker technologies and their clinical application
- Explain appropriate clinical and/or preclinical trial data analysis methods and best practices in clinical and/or preclinical trial design
CONTINUING EDUCATION CREDITS
Continuing Education Credits will be available for the CIWS 2023 program. More information to come soon.